Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Mirum Pharmaceuticals has an average analyst rating of Moderate Buy from 14 analysts (1 sell, 12 buy, 1 strong buy) with a 12‑month average price target of $117.67.
• The company reported Q4 EPS of ($0.11), missing estimates by $0.13, while revenue rose 49.8% to $148.93 million and beat expectations, though margins and return on equity remain negative.
• Corporate insiders have been net sellers — the CEO sold 40,985 shares on March 16 and insiders sold 121,942 shares (~$11.4 million) in the past 90 days, while insiders still own 14.36% of the company.

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $117.6667.

Several brokerages have recently weighed in on MIRM. Stifel Nicolaus increased their price objective on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Royal Bank Of Canada cut their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an "outperform" rating for the company in a research report on Thursday, February 26th. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an "outperform" rating in a report on Monday, December 8th. HC Wainwright reiterated a "buy" rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, March 23rd. Finally, Morgan Stanley boosted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an "overweight" rating in a research report on Friday, January 30th.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $94.17 on Friday. The stock has a market cap of $5.68 billion, a PE ratio of -196.18 and a beta of 0.51. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $109.28. The stock has a fifty day moving average of $96.30 and a 200 day moving average of $82.32.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million during the quarter, compared to analysts' expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company's revenue for the quarter was up 49.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.00 earnings per share. As a group, sell-side analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the sale, the chief executive officer owned 194,309 shares of the company's stock, valued at approximately $17,872,541.82. The trade was a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joanne Quan sold 7,287 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company's stock, valued at approximately $1,735,110.72. The trade was a 27.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 121,942 shares of company stock valued at $11,416,645 in the last ninety days. Corporate insiders own 14.36% of the company's stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $30,000. MCF Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after purchasing an additional 185 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals in the 3rd quarter worth $33,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.